Lesiak Maciej, Łanocha Magdalena, Araszkiewicz Aleksander, Siniawski Andrzej, Grygier Marek, Pyda Małgorzata, Olasińska-Wiśniewska Anna, Iwanczyk Sylwia, Skorupski Włodzimierz, Mitkowski Przemysław, Lesiak Michal Bartosz, Grajek Stefan
1st Department of Cardiology, University of Medical Sciences, Poznan, Poland.
EuroIntervention. 2016 Jun 12;12(2):e144-51. doi: 10.4244/EIJV12I2A27.
Data concerning the use of bioresorbable vascular scaffolds (BVS) for chronic total occlusion (CTO) lesions are limited. The aim of this study was to evaluate the early and midterm clinical outcomes of CTO stenting with BVS.
Forty consecutive patients (male 78%, mean age 59.9±8.3 years, diabetics 30%) with CTO treated with BVS were enrolled. Patients with a reference vessel diameter >4 mm, metallic stents, excessive calcium and tortuosity were excluded. Mean J-CTO score was 1.6. A total of 63 BVS were implanted with an average number of 1.6 per patient, and an average scaffold length of 42.4±21.5 mm. Procedural success was achieved in all patients with no device-related complications. At follow-up (median time 556 days), there were no deaths, one patient experienced subacute and late scaffold thrombosis (ST), and another one developed symptomatic in-scaffold focal restenosis treated with repeat PCI. At control angiography, performed at a median time of 329 days in 27 patients (68%), no more restenosis or vessel reocclusion was found.
CTO stenting with BVS is feasible with good acute performance, and good early and midterm clinical outcomes.
关于生物可吸收血管支架（BVS）用于慢性完全闭塞（CTO）病变的数据有限。本研究的目的是评估使用BVS进行CTO支架置入术的早期和中期临床结果。
连续纳入40例接受BVS治疗的CTO患者（男性占78%，平均年龄59.9±8.3岁，糖尿病患者占30%）。排除参考血管直径>4mm、金属支架、钙化过多和血管迂曲的患者。平均J-CTO评分为1.6。共植入63枚BVS，平均每位患者植入1.6枚，平均支架长度为42.4±21.5mm。所有患者手术成功，无器械相关并发症。随访（中位时间556天）时，无死亡病例，1例患者发生亚急性和晚期支架血栓形成（ST），另1例发生有症状的支架内局灶性再狭窄，接受了重复PCI治疗。在27例患者（68%）中位时间329天进行的对照血管造影中，未发现更多再狭窄或血管再闭塞。
使用BVS进行CTO支架置入术是可行的，具有良好的急性表现以及早期和中期临床结果。
